Literature DB >> 25597755

Response to: Does the Nerium oleander extract PBI-05204 have potential for pancreatic cancer?

Robert A Newman1, Peiying Yang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25597755     DOI： 10.1007/s10637-015-0208-8

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  5 in total

1.  Cyto-/genotoxic effects of the ethanol extract of Chan Su, a traditional Chinese medicine, in human cancer cell lines.

Authors:  Sunyeong Lee; Younghyun Lee; Young Joo Choi; Kyung-Suk Han; Hai Won Chung
Journal:  J Ethnopharmacol       Date:  2014-02-01       Impact factor: 4.360

2.  A hydroalcoholic extract from the leaves of Nerium oleander inhibits glycolysis and induces selective killing of lung cancer cells.

Authors:  José Manuel Calderón-Montaño; Estefanía Burgos-Morón; Manuel Luis Orta; Santiago Mateos; Miguel López-Lázaro
Journal:  Planta Med       Date:  2013-07-03       Impact factor: 3.352

3.  Oleandrin suppresses activation of nuclear transcription factor-kappa B and activator protein-1 and potentiates apoptosis induced by ceramide.

Authors:  Yashin Sreenivasan; Abira Sarkar; Sunil Kumar Manna
Journal:  Biochem Pharmacol       Date:  2003-12-01       Impact factor: 5.858

4.  Oleandrin-mediated inhibition of human tumor cell proliferation: importance of Na,K-ATPase alpha subunits as drug targets.

Authors:  Peiying Yang; David G Menter; Carrie Cartwright; Diana Chan; Susan Dixon; Milind Suraokar; Gabriela Mendoza; Norma Llansa; Robert A Newman
Journal:  Mol Cancer Ther       Date:  2009-08-11       Impact factor: 6.261

5.  First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumors.

Authors:  D S Hong; H Henary; G S Falchook; A Naing; S Fu; S Moulder; J J Wheler; A Tsimberidou; J B Durand; R Khan; P Yang; M Johansen; R A Newman; R Kurzrock
Journal:  Invest New Drugs       Date:  2014-06-13       Impact factor: 3.850
  5 in total
  1 in total

1.  AKT Isoforms as a Target in Cancer and Immunotherapy.

Authors:  Daniel J Smit; Manfred Jücker
Journal:  Curr Top Microbiol Immunol       Date:  2022       Impact factor: 4.737
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.